Israel-Medical-Healthcare

[midastouch017]

Insightec Announces Registration Approval Of Exablate Neuro By Singapore Health Sciences Authority

Positive momentum continues to bring Focused Ultrasound to global patients living with Essential Tremor and Tremor-dominant Parkinson's Disease

http://m.koreaherald.com/amp/view.php?ud=20210705000139

HAIFA, Israel and MIAMI, July 5, 2021 /PRNewswire/ -- Insightec®, a global healthcare company focused on creating the next generation of patient care, announced approval of the Exablate® Neuro platform by the Health Sciences Authority (HSA) in Singapore.

The Exablate Neuro (Exablate 4000) platform uses Focused Ultrasound to ablate a target deep in the brain. The unilateral treatment is suitable for patients with Essential Tremor (age 22 or older) or Tremor-dominant Parkinson's Disease (age 30 or older) who have not responded to medications.

"The value of Focused Ultrasound for medical centers treating movement disorders is greatly improved patient care," said Maurice R. Ferré MD, Insightec CEO and Chairman of the Board of Directors. "Our technology enables patients to go from a life dominated by tremor to the potential for a calm, steady hand."

There are 81 leading medical centers globally that have established Focused Ultrasound programs with Exablate Neuro. Insightec is working with Transmedic Group, a leading distributor of advanced medical technology in Southeast Asia, to advance adoption of the Exablate Neuro in the Singapore market.

"We are excited to bring this transformational technology to medical centers in Singapore," commented Teo Kee Meng, Transmedic Managing Director. "More importantly, patients will now have the option to choose a treatment that is outpatient and incisionless."